Last updated: February 23, 2026
What is NDC 82009-0182?
NDC 82009-0182 refers to a specific pharmaceutical product identified within the National Drug Code (NDC) system. According to available databases, this NDC code corresponds to Sodium Hyaluronate Injection, available in specific strengths and packaging, used primarily for osteoarthritis knee pain and joint lubrication (U.S. Food and Drug Administration, 2023).
Market Size and Demand Dynamics
Estimated Market Size
The global hyaluronic acid-based injectable market was valued at approximately USD 3.4 billion in 2022 and is projected to grow at a CAGR of 7% through 2030 (Grand View Research, 2023). Within this segment, sodium hyaluronate injections constitute a significant subset, particularly driven by osteoarthritis treatment needs.
Key Market Drivers
- Increasing prevalence of osteoarthritis, especially in aging populations.
- Rising interest in minimally invasive procedures.
- Expanding applications for joint lubrication and viscosupplementation.
- Favorable reimbursement policies in key markets like the U.S. and Europe.
Competitive Landscape
Major competitors include:
- Sanofi (Hyalgan)
- Anika Therapeutics (Monovisc)
- Ferring Pharmaceuticals (Euflexxa)
- ZZ Biotech (Supartz)
These products dominate distribution channels, with price points influenced heavily by branding, formulation, and provider reimbursement rates.
Price Analysis
Current Pricing Trends
- Average wholesale price (AWP): Ranges between USD 900 and USD 1,200 per injection session.
- Reimbursement rates: Typically USD 450–USD 750 per injection, influenced by insurance plans and regional policies.
- Packaging and strength variations: Higher volumes or concentrated formulations command premium pricing but can reduce per-use costs at scale.
Price Comparison with Similar Products
| Product |
Typical Price per Injection |
Marketed Strengths |
Notes |
| Hyalgan (Sanofi) |
USD 950 – USD 1,150 |
20 mg/2 mL in prefilled syringes |
Widely used, established brand |
| Monovisc (Anika) |
USD 950 – USD 1,050 |
24 mg/3 mL, single injection |
Addresses convenience in dosing |
| Euflexxa (Ferring) |
USD 900 – USD 1,200 |
20 mg/2 mL in single-dose syringes |
Regarded for high purity |
Price Prospects – 2023 to 2028
Analysts project a moderate price stabilization with potential for discounts driven by increased competition and biosimilar entry. Specific to NDC 82009-0182:
- Short-term (2023–2025): Prices may decline by 5–10% due to biosimilar competition.
- Medium-term (2025–2028): Prices could stabilize at USD 850–USD 1,000 per injection, driven by market consolidation and payer negotiations.
Regulatory and Reimbursement Outlook
- FDA approvals: The product's origin and approval status influence market penetration. A new submission or label update prompts shifts in pricing strategies.
- Reimbursement policies: Governments and private payers set reimbursement levels, influencing net pricing. Favorable policies support price stability.
- Generics/biosimilars: Entry of biosimilar versions could reduce prices by 20–30% within the next 3–5 years, as seen in other biologic markets (IQVIA, 2022).
Market Entry Barriers
- High manufacturing complexity and stringent regulatory standards.
- Patent protections and exclusivity periods.
- Established list of competitors with strong distribution networks.
Strategic Implications
- Formulation innovations—e.g., extended-release or combo formulations—might command premium pricing.
- Contracting and volume-based discounts will likely influence net prices.
- Regional expansion, particularly into emerging markets, presents opportunities for price growth.
Summary
The sodium hyaluronate injection market driven by NDC 82009-0182 is characterized by steady demand, competitive pressures, and pricing stability supported by high efficacy and reimbursement. Price reductions are anticipated through biosimilar entry and increased competition, yet brand loyalty and differentiated formulations could sustain premium pricing in niche segments.
Key Takeaways
- The global hyaluronic acid injection market was valued at USD 3.4 billion in 2022, projected to grow at 7% CAGR.
- Current prices range USD 900–USD 1,200 per injection, with reimbursement rates slightly lower.
- Price reductions of 20–30% are forecasted over five years due to biosimilar competition.
- Market dynamics are influenced by regulatory approvals, reimbursement policies, and regional expansion.
- Innovation in formulations could sustain higher price points.
Frequently Asked Questions
1. What factors influence the price of sodium hyaluronate injections like NDC 82009-0182?
Market demand, manufacturing costs, competitive landscape, reimbursement policies, and regulatory approval status all influence pricing.
2. How might biosimilars impact the pricing of this drug?
Biosimilar entry typically leads to price reductions of 20–30%, increasing competition and reducing brand premiums.
3. What are the key markets for sodium hyaluronate injections?
The U.S., Europe, and Japan are primary markets, with expansion opportunities in emerging countries.
4. Are there significant patent protections protecting this product?
Patent protections and biologic exclusivities affect market entry. Once expired, biosimilars are more likely to compete.
5. What strategies could manufacturers employ to maintain price premiums?
Formulation innovations, expanding indications, and improving delivery methods are potential strategies.
References
[1] Grand View Research. (2023). Hyaluronic Acid Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Biosimilar Market Report.
[3] U.S. Food and Drug Administration. (2023). NDC Directory.
